A Phase 1B/2 Study To Evaluate The Safety And Efficacy Of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose Ara-C Or Decitabine In Patients With Acute Myeloid Leukemia Or High Risk Myelodysplastic Syndrome
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of participants with Dose-limiting toxicities (DLT)
1 -year
Yes
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
B1371003
NCT01546038
July 2012
November 2015
Name | Location |
---|---|
Pfizer Investigational Site | Atlanta, Georgia 30342 |
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Federal Way, Washington 98003 |
Pfizer Investigational Site | Aurora, Colorado 80012 |
Pfizer Investigational Site | Clearwater, Florida 33761 |
Pfizer Investigational Site | Kansas City, Kansas 66112 |
Pfizer Investigational Site | North Adams, Massachusetts 01247 |
Pfizer Investigational Site | Columbia, Missouri 65201 |
Pfizer Investigational Site | Bristol, Tennessee 37620 |
Pfizer Investigational Site | Livingston, New Jersey 07039 |